ERBB2 and non-small cell lung carcinoma: However, no clinical study has evaluated the first‐line benefit of targeted therapy, including DS‐8201, other anti‐HER2 agents, small‐molecule tyrosine kinase inhibitors (TKIs), or antibody‐conjugating drugs for HER2‐altered NSCLC.